{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:24:38Z","timestamp":1784939078672,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-01974"],"award-info":[{"award-number":["2016-01974"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006741","name":"Stiftelsen Frimurare Barnhuset i Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006741","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Karolinska Institutet Research Foundation"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40261-020-00977-5","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T11:04:22Z","timestamp":1603710262000},"page":"1147-1154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Data Mining for Adverse Events of Tumor Necrosis Factor-Alpha Inhibitors in Pediatric Patients: Tree-Based Scan Statistic Analyses of Danish Nationwide Health Data"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7759-0887","authenticated-orcid":false,"given":"Viktor","family":"Wintzell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Svanstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Melbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kulldorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"issue":"3","key":"977_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132(3):863\u201373 (Quiz 1165\u20131166).","journal-title":"Gastroenterology"},{"issue":"3","key":"977_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ibd.20788","volume":"15","author":"FM Ruemmele","year":"2009","unstructured":"Ruemmele FM, Lachaux A, Cezard JP, et al. Efficacy of infliximab in pediatric Crohn\u2019s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis. 2009;15(3):388\u201394.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"977_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","volume":"10","author":"J Hyams","year":"2012","unstructured":"Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391\u20139 (e391).","journal-title":"Clin Gastroenterol Hepatol."},{"key":"977_CR4","doi-asserted-by":"publisher","unstructured":"Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011(2):CD008794. https:\/\/doi.org\/10.1002\/14651858.CD008794.pub2","DOI":"10.1002\/14651858.CD008794.pub2"},{"issue":"9990","key":"977_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258\u201365.","journal-title":"Lancet"},{"issue":"11","key":"977_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2468-1253(19)30266-3","volume":"4","author":"V Wintzell","year":"2019","unstructured":"Wintzell V, Svanstr\u00f6m H, Melbye M, et al. Use of tumour necrosis factor-\u03b1 inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study. Lancet Gastroenterol Hepatol. 2019;4(11):845\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"18","key":"977_CR7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJMhpr021646","volume":"347","author":"R Steinbrook","year":"2002","unstructured":"Steinbrook R. Testing medications in children. N Engl J Med. 2002;347(18):1462\u201370.","journal-title":"N Engl J Med"},{"key":"977_CR8","unstructured":"Field MJ, Behrman RE, editors. Ethical conduct of clinical research involving children. National Academies Press, US; 2004."},{"key":"977_CR9","unstructured":"Council of Canadian Academies. Improving medicines for children in Canada. Ottawa, ON: The Expert Panel on Therapeutic Products for Infants, Children, and Youth, Council of Canadian Academies; 2014."},{"issue":"9","key":"977_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMhle1901265","volume":"381","author":"FT Bourgeois","year":"2019","unstructured":"Bourgeois FT, Kesselheim AS. Promoting pediatric drug research and labeling\u2014outcomes of legislation. N Engl J. 2019;381(9):875\u201381.","journal-title":"N Engl J."},{"key":"977_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev-pharmtox-011613-135955","volume":"55","author":"S Hennessy","year":"2015","unstructured":"Hennessy S, Strom BL. Improving postapproval drug safety surveillance: getting better information sooner. Annu Rev Pharmacol Toxicol. 2015;55:75\u201387.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"977_CR12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"977_CR13","unstructured":"Sundhetsstyrelsen. Fokusrapport\u2014Overv\u00e5gning af bivirkninger hos b\u00f8rn med autoimmune sygdomme i biologisk behandling. Sundhetsstyrelsen; 2012. https:\/\/laegemiddelstyrelsen.dk\/~\/media\/85FC2763F2E84E7CB354E1AAF0527199.ashx"},{"issue":"3","key":"977_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivariate Behav Res."},{"issue":"2","key":"977_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/1541-0420.00039","volume":"59","author":"M Kulldorff","year":"2003","unstructured":"Kulldorff M, Fang Z, Walsh S. A tree-based scan statistic for database disease surveillance. Biometrics. 2003;59(2):323\u201331.","journal-title":"Biometrics"},{"issue":"6","key":"977_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/EDE.0000000000000907","volume":"29","author":"SV Wang","year":"2018","unstructured":"Wang SV, Maro JC, Baro E, et al. data mining for adverse drug events with a propensity score-matched tree-based scan statistic. Epidemiology. 2018;29(6):895\u2013903.","journal-title":"Epidemiology."},{"issue":"5","key":"977_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.3423","volume":"22","author":"M Kulldorff","year":"2013","unstructured":"Kulldorff M, Dashevsky I, Avery TR, et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013;22(5):517\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"977_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/pds.4397","volume":"27","author":"R Li","year":"2018","unstructured":"Li R, Weintraub E, McNeil MM, et al. Meningococcal conjugate vaccine safety surveillance in the vaccine safety datalink using a tree-temporal scan data mining method. Pharmacoepidemiol Drug Saf. 2018;27(4):391\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"977_CR19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/aje\/kwz104","volume":"188","author":"WK Yih","year":"2019","unstructured":"Yih WK, Kulldorff M, Dashevsky I, Maro JC. Using the self-controlled tree-temporal scan statistic to assess the safety of live attenuated herpes zoster vaccine. Am J Epidemiol. 2019;188(7):1383\u20138.","journal-title":"Am J Epidemiol"},{"key":"977_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1214\/aoms\/1177707045","volume":"28","author":"M Dwass","year":"1957","unstructured":"Dwass M. Modified randomization tests for nonparametric hypotheses. Ann Math Stat. 1957;28:181\u20137.","journal-title":"Ann Math Stat."},{"issue":"3","key":"977_CR21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s10620-018-4921-y","volume":"63","author":"P Andrade","year":"2018","unstructured":"Andrade P, Lopes S, Gaspar R, Nunes A, Magina S, Macedo G. Anti-tumor necrosis factor-alpha-induced dermatological complications in a large cohort of inflammatory bowel disease patients. Dig Dis Sci. 2018;63(3):746\u201354.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"977_CR22","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","volume":"110","author":"E Freling","year":"2015","unstructured":"Freling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186\u201396.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"977_CR23","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/ibd\/izy112","volume":"24","author":"S Sridhar","year":"2018","unstructured":"Sridhar S, Maltz RM, Boyle B, Kim SC. Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. Inflamm Bowel Dis. 2018;24(9):2086\u201392.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"977_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/MPG.0000000000002349","volume":"69","author":"O Courbette","year":"2019","unstructured":"Courbette O, Aupiais C, Viala J, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;69(2):189\u201393.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"977_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MPG.0b013e3181f3d9ab","volume":"52","author":"G Hiremath","year":"2011","unstructured":"Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52(2):230\u20132.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"977_CR26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/MIB.0000000000000088","volume":"20","author":"T Malkonen","year":"2014","unstructured":"Malkonen T, Wikstrom A, Heiskanen K, et al. Skin reactions during anti-TNFalpha therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20(8):1309\u201315.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"977_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamapediatrics.2019.2662","volume":"173","author":"A Butwicka","year":"2019","unstructured":"Butwicka A, Olen O, Larsson H, et al. Association of childhood-onset inflammatory bowel disease with risk of psychiatric disorders and suicide attempt. JAMA Pediatr. 2019;173(10):969\u201378.","journal-title":"JAMA Pediatr"},{"issue":"4","key":"977_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep."},{"issue":"4","key":"977_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pds.4107","volume":"26","author":"S Suissa","year":"2017","unstructured":"Suissa S, Moodie EE, Dell\u2019Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459\u201368.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"977_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/CLEP.S99478","volume":"8","author":"L Larsen","year":"2016","unstructured":"Larsen L, Jensen MD, Larsen MD, et al. The Danish National Registry for biological therapy in inflammatory bowel disease. Clin Epidemiol. 2016;8:607\u201312.","journal-title":"Clin Epidemiol"},{"key":"977_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","journal-title":"Clin Epidemiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00977-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:34:47Z","timestamp":1635208487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00977-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00977-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"assertion":[{"value":"7 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Karolinska Institute. This study was supported by the Swedish Research Council (2016-01974), Frimurare Barnhuset Foundation, and the Karolinska Institutet Research Foundation. Pasternak was supported by an investigator grant from the Strategic Research Area Epidemiology program at Karolinska Institutet. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.F. Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBREG) outside the submitted work. That study has received funding from Janssen corporation. H. Svanstr\u00f6m reports consulting fees from Celgene and employment at IQVIA outside the submitted work. V. Wintzell, M. Melbye, B. Pasternak, and M. Kulldorff have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No approval was needed because this was a register-based study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required because the analysis was based on secondary register data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors consented to publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not available.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"VW had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: VW, HS, BP, MK. Acquisition of data: BP. Analysis and interpretation of data: All authors. Drafting of the manuscript: VW. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: VW. Obtained funding: BP. Study supervision: BP, MK.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}